CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, X.
Right arrow Articles by Burns, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, X.
Right arrow Articles by Burns, P. A.

Cancer Epidemiology Biomarkers & Prevention, Vol 6, Issue 8 611-616, Copyright © 1997 by American Association for Cancer Research


ARTICLES

A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer

X Xu, MJ Stower, IN Reid, RC Garner and PA Burns
Institute of Pathology, Algernon Firth Building, University of Leeds, United Kingdom.

Twenty-eight transitional cell carcinomas of the bladder, grade 2 or 3, were analyzed for the presence of p53 mutations. Thirteen tumors were found to contain 14 mutations. These were all base substitution mutations, of which nine were GC-->AT transitions (three at CpG sites). The remaining five mutations were transversions (three GC-->CG, one GC-->TA, and one AT-->TA). Four of the mutations were found at codon 280. A comparison with other studies of bladder tumors reveals that a region encompassing codons 280 and 285 represents a hot spot for p53 mutation in bladder cancer. The 280/285 hot spot lies within two purine-rich sequences that may provide some clues to the identity of potential bladder carcinogens. A comparison of mutations from bladder tumors of smokers and nonsmokers reveals no significant differences.


This article has been cited by other articles:


Home page
CarcinogenesisHome page
H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al.
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens
Carcinogenesis, January 1, 2005; 26(1): 177 - 184.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers
Carcinogenesis, January 1, 2000; 21(1): 101 - 106.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Yamamoto, A. Romanenko, M. Wei, C. Masuda, W. Zaparin, W. Vinnichenko, A. Vozianov, C. C. R. Lee, K. Morimura, H. Wanibuchi, et al.
Specific p53 Gene Mutations in Urinary Bladder Epithelium after the Chernobyl Accident
Cancer Res., August 1, 1999; 59(15): 3606 - 3609.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.